Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial.

Mohammad BosaeedEbrahim MahmoudAhmad AlharbiHadeel AltayibHawra AlbayatFaisal AlharbiKhalid GhalilahAbdulmajid Al ArfajJumana AlJishiAbdullatif AlarfajHajar AlqahtaniBadriah M AlmutairiManar AlmaghaslahNawaf M AlyahyaAbdullah BawazirSaud AlEisaAbdulrahman AlsaedyAbderrezak BouchamaMalak AlharbiMajid AlShamraniSameera Al JohaniMajed AljeraisyMohammed AlzahraniAbdulhakeem O AlthaqafiHassan AlmarhabiAthari AlotaibiNasser AlqahtaniYaseen M ArabiOmar S AldibasiAhmad Alaskar

Published in: Infectious diseases and therapy (2021)

ClinicalTrials.gov (NCT04392973).

Keyphrases

combination therapy
study protocol
randomized controlled trial
coronavirus disease
sars cov
double blind
phase iii
clinical trial
early onset
high intensity
phase ii
open label
cross sectional
respiratory syndrome coronavirus
drug induced